ADB-FUBINACA is a
designer drug
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Des ...
identified in
synthetic cannabis blends in Japan in 2013.
In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the
Drug Enforcement Administration
The Drug Enforcement Administration (DEA; ) is a Federal law enforcement in the United States, United States federal law enforcement agency under the U.S. Department of Justice tasked with combating drug trafficking and distribution within th ...
.
The (''S'')-enantiomer of ADB-FUBINACA is described in a 2009
Pfizer
Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfize ...
patent
A patent is a type of intellectual property that gives its owner the legal right to exclude others from making, using, or selling an invention for a limited period of time in exchange for publishing an sufficiency of disclosure, enabling disclo ...
and has been reported to be a potent
agonist
An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ago ...
of the
CB1 receptor and the
CB2 receptor with
EC50 values of 1.2 nM and 3.5 nM, respectively.
[ ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and ]STS-135
STS-135 (ISS assembly flight ULF7) was the 135th and final mission of the American Space Shuttle program. It used the orbiter '' Atlantis'' and hardware originally processed for the STS-335 contingency mission, which was not flown. STS-135 l ...
. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA
AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with ''K''i values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by P ...
only by the replacement of the isopropyl group with a ''tert''-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
Side effects
One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication.
At least an additional 8 deaths in Hungary in 2015 are linked to the usage of this material, all deaths were youngsters below 21.
Metabolism
Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.
Legality
In the United States, ADB-FUBINACA is a Schedule I controlled substance
This is the list of Schedule I drugs as defined by the United States Controlled Substances Act.21 CFRbr>1308.11(CSA Sched I) with changes through (Oct 18, 2012). Retrieved September 6, 2013. The following findings are required for drugs to be pla ...
.
See also
* 5F-AB-PINACA
5F-AB-PINACA is an indazole-based synthetic cannabinoid that is derived from a series of compounds originally developed by Pfizer in 2009 as an analgesic medication, and has been sold online as a designer drug.
5F-AB-PINACA has been reported t ...
* 5F-ADB
5F-ADB (also known as 5F-MDMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products and has been sold online as a designer drug. 5F- ...
* 5F-AMB
5F-AMB (also known as 5F-MMB-PINACA and 5F-AMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products. It was first identified in Jap ...
* 5F-APINACA
5F-APINACA (also known as 5F-AKB-48 or 5F-AKB48) is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with a 5-fluoropent ...
* AB-CHFUPYCA
* AB-PINACA
AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.
It was originally developed by Pfizer in 2009 as an analgesic medication.
AB-PINACA acts as a potent agonist for the CB1 recepto ...
* ADB-BINACA
* ADB-CHMINACA
* ADB-PINACA
ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively. Like MDMB-FUBINA ...
* ADBICA
ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBI ...
* ADSB-FUB-187
* APINACA
* MDMB-CHMICA
* MDMB-FUBINACA
* PF-03550096
* PX-3
PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic
...
References
{{Cannabinoids
Cannabinoids
Designer drugs
Fluoroarenes
Indazolecarboxamides
Tert-butyl compounds